Targeting immune checkpoints and immune-infiltrating cells within the TIME can enhance anti-tumor immune responses and improve the efficacy of ICIs, with combination therapies such as PD-1/CTLA-4 dual blockade emerging as a principal strategy to enhance the therapeutic outcomes of ICI [83,84,85]. Here, CTLA4 is linked to neoplasm.